

T. Tachikawa, K. Nose, T. Ohmori, M. Adachi (Eds.)

**New Trends in the Molecular and
Biological Basis for Clinical Oncology**

T. Tachikawa, K. Nose,
T. Ohmori, M. Adachi (Eds.)

New Trends in the Molecular and Biological Basis for Clinical Oncology

 Springer

Tetsuhiko Tachikawa, D.D.S., Ph.D.
Professor and Chairman
Department of Oral Pathology and Diagnosis
Showa University School of Dentistry
1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Kiyoshi Nose, Ph.D.
Professor and Chairman
Department of Microbiology
Showa University School of Pharmaceutical Sciences
1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Tohru Ohmori, M.D., Ph.D.
Associate Professor
Institute of Molecular Oncology
Showa University
1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Mitsuru Adachi, M.D., Ph.D.
Professor and Chairman
Division of Allergology and Respiratory Medicine
Department of Internal Medicine
(First Department of Internal Medicine)
Showa University School of Medicine
1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan

Library of Congress Control Number: 2008937890

ISBN 978-4-431-88662-4 Springer Tokyo Berlin Heidelberg New York
e-ISBN 978-4-431-88663-1

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Springer is a part of Springer Science+Business Media
springer.com
© Springer 2009
Printed in Japan

Typesetting: Camera-ready by the editors and authors
Printing and binding: Kato Bunmeisha, Japan

Printed on acid-free paper

Foreword

On behalf of Showa University, I am pleased to publish the proceedings of The 4th Annual Meeting of the Showa International Symposium for Life Sciences, *New Trends in the Molecular and Biological Basis for Clinical Oncology*.

This symposium aims for the improvement in the prevention and therapeutics for intractable diseases and has been held annually for the past four years. It always provides us with a great opportunity to share the latest knowledge in fundamental, translational, and clinical fields about intractable diseases. In last year's symposium we focused on medical oncology. The proceedings is composed of 18 articles presenting the latest data about new strategies for cancer therapeutics. Six specialists of the contributors are invited from all over the world.

I hope that this book will furnish valuable information for the development of clinical as well as basic cancer research to all who are working in this field.

Katsuji Oguchi, M.D., Ph.D.
Chairman, Board of Directors of Showa University
Tokyo, Japan
June 2008

Foreword

Recently, many cancer patients have experienced the hope of being treated with the latest cancer therapy by specialists in oncology. It is obvious, however, that the number of oncologists is absolutely inadequate to meet the demand nationwide, because medical oncology has not been authorized in the ministry's curriculum guideline and cancer therapeutics has not been included among the special subjects of medical schools in Japan. Accordingly, the establishment of an education system for oncology to produce many experts in cancer therapeutics is the prime task of medical schools. Consequently, many medical schools in Japan have begun to set up departments of clinical oncology in their hospitals, and we also have decided to establish such a department in our hospital. I believe that the work of clinical oncology should be further accelerated for the benefit of cancer patients in this country.

Especially under these circumstance, it is my great pleasure to publish *New Trends in the Molecular and Biological Basis for Clinical Oncology*, the proceedings of The 4th Annual Meeting of the Showa International Symposium for Life Sciences, which was held at Showa University on October 6th, 2007. On behalf of the university, I am grateful to all the contributors to this book, who are active leaders in clinical oncology and in cancer research.

Akiyoshi Hosoyamada, M.D., Ph.D.
President, Showa University
Tokyo, Japan
June 2008

Foreword

A long time has passed since cancer became the primary cause of death in Japan. In fact, the number of cancer patients is still growing, and one-third of clinical deaths are caused by this disease. It is estimated that in tandem with the rapid transition to an aging society, the increment in the number of cancer patients will accelerate. It is obvious that the conquest of cancer is still one of the largest medical problems to be solved.

Recently, remarkable progress in cancer therapy has been made possible by better understanding of the molecular and cell biology of cancer and by the technology that has resulted in the discovery of new drugs. The molecular target cancer drugs are being developed constantly and with astonishing speed, and at the same time many large-scale clinical studies are being conducted all over the world. In order to utilize these cancer drugs properly, the efficacy of each of them must be proved by their own clinical studies. However, evaluation in clinical studies is not sufficient to select the optimal drug for each individual patient, because the impact of the molecular target drugs is dependent on the “individuality” of cancer. For this purpose, we have to solve the following additional problems:

- 1) Proof that a molecular target drug can actually inhibit the expected target in vivo (proof of principle)
- 2) Detection of a clinical marker from patient materials correlated with drug efficacy (surrogate marker)

As these challenges can be met only through close cooperation between basic and clinical cancer research, I think that we should establish an efficient new research system, breaking down the barrier between those two areas of research. There is only cancer research for the benefit of patients. We must be united as one body of researchers, wishing to cure cancer.

Hajime Yasuhara, M.D., Ph.D.
Dean, Showa University School of Medicine
Tokyo, Japan
June 2008

Preface

Several years ago, molecular target anticancer drugs began to be used in the clinical field, showing outstanding clinical efficacy. These newly developed drugs have a great effect even on intractable cancers such as hepatoma and renal cell carcinoma. Fortunately, we are now facing a surge of new findings in the development of cancer therapy. Cancer research is becoming a multidisciplinary field that includes nearly all areas of science and technology. In fact, many anticancer drugs are developed by basic cancer research that is increasingly influenced by clinical observations. At the same time, the molecular and genetic observations of epidemiology have great influence on research protocols in both the laboratory and the clinic. We are convinced that such cooperation across basic, translational, and clinical research fields will rapidly advance cancer therapeutics beneficial to cancer patients.

Under these circumstances, we held The 4th Annual Meeting of Showa International Symposium for Life Sciences with the theme “New Trends in the Molecular and Biological Basis for Clinical Oncology” at Showa University, Tokyo, in October 2007. This book contains the materials from that symposium in which new strategies for the development of cancer therapeutics were discussed. In the first chapter, we focus on the cancer therapy targeting receptor tyrosine kinases aimed at clinical utilization of new signaling regulations. The second chapter explains the interaction between cancer progression and extracellular environments such as inflammatory cytokines and the extracellular matrix. The third describes investigation of the biomarkers for personalized cancer therapy, using microarray analysis and pharmacogenomics technology. This book also includes several reports of the latest investigations dealing with cancer cell biology and therapeutics.

We thank all the authors and others who have contributed to the publication of this book. We believe that its contents are valuable for investigators in cancer research and that their achievements will help to provide the best possible care for individual cancer patients in the near future.

Tetsuhiko Tachikawa, Professor of Oral Pathology
Kiyoshi Nose, Professor of Microbiology
Tohru Ohmori, Associate Professor of Molecular Oncology
Mitsuru Adachi, Professor of Internal Medicine
Showa University, Tokyo, Japan
June 2008

Acknowledgments

The 4th Annual Meeting of the Showa International Symposium for Life Sciences was supported in part by Grants for the Promotion of the Advancement of Education and Research in Graduate Schools and Ordinary Expenses for Private Schools from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

We would like to acknowledge the extraordinary contributions of Mrs. Noriko Shishido, who played a vital role in the preparation of this book and assumed responsibility for the organization and compilation of all the chapters. We are grateful for her dedication.

TT
KN
TO
MA

Contents

Foreword	V
Preface	VIII
Acknowledgement	IX
Contributors	XIII
Color Plates.....	XIX

Part I. RTK-Related Signaling

HER2 Overexpression Attenuates the Antiproliferative Effect of Aromatase Inhibitor in MCF-7 Breast Cancer Cells Stably Expressing Aromatase I. Shin, T. Miller, E. S. Wang, and C. L. Arteaga.	3
Biomarker Research for Development of Molecular Target Agents K. Nishio and T. Arao	29
Epidermal Growth Factor (EGF) Receptor Kinase Activity is Required for Tumor Necrosis Factor (TNF)- α Mediated Intestinal Epithelial Survival T. Yamaoka, D. B. Polk, T. Ohmori, S. Kusumoto, T. Sugiyama, T. Shirai, M. Nakashima, K. Okuda, T. Hirose, T. Ohnishi, N. Horichi, and M. Adachi	37
A Molecular Mechanism of Diminished Binding Activity between 15 bp Deletion Mutant EGFR and c-Cbl Ubiquitin Ligase T. Ohmori, T. Hosaka, T. Kanome, F. Inoue, K. Ando, T. Hirose, T. Kadofuku, and M. Adachi	55

Part II. Inflammation, Angiogenesis, and Tumor Progression

TGF β -Mediated Epithelial Mesenchymal Transition and Metastasis in Skin and Head-and-Neck Cancer S. Bornstein, G. W. Han, K. Hoot, S. L. Lu, and X. J. Wang	69
---	----

TGF- β and Tumor Progression Mediated by Reactive Oxygen Species K. Nose, T. Sugimoto, M. Wakamatsu, F. Ishikawa, and M. Shibamura	81
Role of MT1-MMP in Tumor-Stromal Interaction M. Seiki	86
Role of Proinflammatory Prostaglandin E ₂ in Bladder Tumor Progression S. Hara	92
 Part III. Biomarkers for Clinical Oncology	
Molecular Biomarker for Lung Cancer H. Y. Chen and P. C. Yang	99
Screening of Biomarker for Oral Squamous Cell Carcinoma Correlating with Clinicopathological Findings Using by Laser Microdissection and cDNA Microarray T. Irié, G. Yamamoto, T. Isobe, T. Matsunaga, and T. Tachikawa.....	106
Biomarkers for Clinical Oncology Y. Sasaki	117
Genome-Wide cDNA Microarray Screening of Gene Expression Profiles Correlated with Resistance to Anti-Cancer Drug Treatment and Radiation in Oral Squamous Cell Carcinoma S. Shintani	118
 Part IV. Poster Session	
Drug Accumulation and Efflux Do not Contribute to Acquired Gefitinib Resistance S. Kusumoto, T. Sugiyama, M. Nakashima, T. Yamaoka, T. Hirose, T. Ohnishi, N. Horichi, M. Adachi, K. Nishio, N. Saijo, T. Kuroki, and T. Ohmori	127

Difference of EGFR-Binding Proteins between Wild Type and Mutant EGFR T. Kadofuku, T. Kanome, K. Nishio, T. Kuroki, and T. Ohmori	132
Competitive Nuclear Export of Cyclin D1 and Hic-5 Regulates Anchorage-Dependence of Cell Growth and Survival K. Mori, Y. Oshima, K. Nose, and M. Shibamura	139
Induction of Matrix Metalloprotease Gene Expression in an Endothelial Cell Line by Direct Interaction with Malignant Cells K. Egawa, Y. Hasebe, M. Shibamura, and K. Nose	153
Expression of Rad21 Cleaved Products in Oral Epithelium G. Yamamoto, T. Matsunaga, T. Isobe, T. Irie, and T. Tachikawa.....	157
Telomerase-Specific Replication-Selective Virotherapy for Oral Squamous Cell Carcinoma Cell Lines Y. Kurihara, Y. Watanabe, T. Kojima, T. Shiota, M. Hatori, Y. Urata, T. Fujiwara, and S. Shintani	168
Hypoxia Induces Resistance to 5-Fluorouracil in Oral Cancer Cells via G1 Phase Cell Cycle Arrest S. Yoshida, D. Ito, T. Nagumo, T. Shiota, M. Hatori, and S. Shintani	184
Key Word Index	191

Contributors

Adachi, M., First Department of Internal Medicine, School of Medicine, Showa University, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8666, Japan

Ando, K., First Department of Internal Medicine, School of Medicine, Showa University, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8666, Japan

Arao, T., Department of Genome Biology, Kinki University School of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka 589-8511, Japan

Arteaga, C.L., Department of Cancer Biology and Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

Bornstein, S., Departments of Otolaryngology, Cell & Developmental Biology, and Dermatology, Oregon Health & Science University, Portland, OR, USA

Chen, H.-Y., Institute of Statistical Science, Academia Sinica, 128, Sec. 2, Academia Road, Taipei 115, Taiwan

Egawa, K., Department of Microbiology, Showa University School of Pharmaceutical Sciences, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Fujiwara, T., Division of Surgical Oncology, Department of Surgery, Okayama University, Graduate School of Medicine and Dentistry, Okayama, Japan; Center for Gene and Cell Therapy, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

Han, G.W., Departments of Otolaryngology, Cell & Developmental Biology, and Dermatology, Oregon Health & Science University, Portland, OR; Departments of Pathology and Otolaryngology, University of Colorado Denver, Aurora, CO, USA

Hara, S., Department of Health Chemistry, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Hasebe, Y., Department of Microbiology, Showa University School of Pharmaceutical Sciences, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Hatori, M., Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo 145-8515, Japan

Hirose, T., First Department of Internal Medicine, School of Medicine, Showa University, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8666, Japan

Hoot, K., Departments of Otolaryngology, Cell & Developmental Biology, and Dermatology, Oregon Health & Science University, Portland, OR, USA

Horichi, N., First Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan

Hosaka, T., First Department of Internal Medicine, School of Medicine, Showa University, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Inoue, F., Institute of Molecular Oncology, Showa University, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Irié, T., Department of Oral Pathology and Diagnosis, Showa University School of Dentistry, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Ishikawa, F., Department of Microbiology, Showa University School of Pharmaceutical Sciences, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Isobe, T., Department of Oral Pathology and Diagnosis, Showa University School of Dentistry, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Ito, D., Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo 145-8515, Japan

Kadofuku, T., Institute of Molecular Oncology, Showa University, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Kanome, T., Institute of Molecular Oncology, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Kojima, T., Division of Surgical Oncology, Department of Surgery, Okayama University, Graduate School of Medicine and Dentistry, Okayama, Japan; Center for Gene and Cell Therapy, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

Kurihara, Y., Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo 145-8515, Japan

Kuroki, T., Gifu University, 1-1 Yanagido Gifu-shi, Gifu 501-1194, Japan

Kusumoto, S., First Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan

Lu, S.L., Departments of Otolaryngology, Cell & Developmental Biology, and Dermatology, Oregon Health & Science University, Portland, OR; Departments of Pathology and Otolaryngology, University of Colorado Denver, Aurora, CO, USA

Matsunaga, T., Department of Oral Pathology and Diagnosis, Showa University School of Dentistry, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Miller, T., Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

Mori, K., Department of Microbiology, Showa University School of Pharmaceutical Sciences, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Nagumo, T., Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo 145-8515, Japan

Nakashima, M., First Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan

Nishio, K., Department of Genome Biology, Kinki University School of Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka 589-8511, Japan

Nose, K., Department of Microbiology, Showa University School of Pharmaceutical Sciences, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Ohmori, T., Institute of Molecular Oncology, Showa University, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Ohnishi, T., First Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan

Okuda, K., First Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan

Oshima, Y., Department of Microbiology, Showa University School of Pharmaceutical Sciences, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Polk, D.B., Department of Pediatrics, Cell and Developmental Biology, Vanderbilt University School of Medicine, 1025 MRBIV, Nashville, TN 37232-0696, USA

Saijo, N., Internal Medicine, National Cancer Center Hospital East, 6-5-1 Kashino-ha Kashiwa-shi Chiba 277-8577, Japan

Sasaki, Y., Department of Medical Oncology, Saitama International Medical Center – Comprehensive Cancer Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan

Seiki, M., Division of Cancer Cell Research, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokane-dai, Minato-ku, Tokyo 108-8639, Japan

Shibanuma, M., Department of Microbiology, Showa University School of Pharmaceutical Sciences, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan

Shin, I., Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA; Department of Life Science, Hanyang University, Seoul 133-791, Korea

Shintani, S., Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo 145-8515, Japan

Shirai, T., First Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan

Shirota, T., Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo 145-8515, Japan

Sugimoto, T., Department of Microbiology, Showa University School of Pharmaceutical Sciences, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Sugiyama, T., First Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan

Tachikawa, T., Department of Oral Pathology and Diagnosis, Showa University School of Dentistry, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Urata, Y., Oncolys BioPharma, Inc., 3-16-33 Roppongi, Minato-ku, Tokyo 106-0032, Japan

Wakamatsu, M., Department of Microbiology, Showa University School of Pharmaceutical Sciences, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Wang, E.S., Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

Wang, X.-J., Departments of Otolaryngology, Cell & Developmental Biology, and Dermatology, Oregon Health & Science University, Portland, OR; Departments of Pathology and Otolaryngology, University of Colorado Denver, Aurora, CO, USA

Watanabe, Y., Center for Gene and Cell Therapy, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan; Oncolys BioPharma, Inc., 3-16-33 Roppongi, Minato-ku, Tokyo 106-0032, Japan


Yamamoto, G., Department of Oral Pathology and Diagnosis, Showa University School of Dentistry, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142-8555, Japan

Yamaoka, T., First Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan


Yang, P.-C., Department of Internal Medicine, National Taiwan University Collage of Medicine, 1, Sec 1, Ren-Ai Rd, Taipei 100, Taiwan

Yoshida S., Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University, 2-1-1 Kitasenzoku, Ohta-ku, Tokyo 145-8515, Japan


Color Plates




Part I: Yamaoka et al (Fig.1A)




Part I: Ohmori et al (Fig.6)




Part II: Nose et al (Fig.3)






Part III: Shintani et al (Fig.3)



Part IV: Kadofuku et al (Fig.1)



Part IV: Mori et al (Fig.3a)



Part IV: Yamamoto et al (Figs.1, 3-5)